Genvoya ^*

Genvoya is a fixed-dose combination antiretroviral therapy used for the treatment of HIV-1 infection in adults and adolescents. It is designed as a complete treatment regimen in a single daily tablet, simplifying HIV management and improving adherence to therapy. The medication contains four active components that target HIV replication at different stages: Elvitegravir – an integrase strand transfer inhibitor that blocks the integration of HIV genetic material into human immune cells. Cobicistat – a pharmacokinetic enhancer (“booster”) that increases the effectiveness of elvitegravir by slowing its breakdown in the liver. Emtricitabine – a nucleoside reverse transcriptase inhibitor (NRTI) that interferes with HIV’s ability to replicate its RNA into DNA. Tenofovir alafenamide (TAF) – another NRTI that prevents viral replication while generally causing less kidney and bone toxicity than older tenofovir formulations. By combining these four drugs, Genvoya effectively reduces the amount of HIV in the blood (viral load), allowing the immune system to recover and lowering the risk of progression to AIDS and HIV transmission. While it does not cure HIV, consistent use can keep the virus suppressed to undetectable levels. Genvoya is typically prescribed by HIV specialists and is available in many countries, including the UK and Israel, where it may also be marketed under alternative brand names such as Gendevra depending on regulatory registration and local distribution.